Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability

Drug-induced proarrhythmia is a rare but potentially lethal adverse drug reaction. To test whether the SCREENIT system (an automated computerized test apparatus), using an isolated perfused heart obtained from female rabbits, could correctly identify agents that lengthen the action potential duration (APD) and drugs known to induce proarrhythmia, 14 drugs (penicillin G, haloperidol, adriamycin, indapamide, verapamil, aspirin, lidocaine, clomipramine, propranolol, erythromycin, quinidine, terfenadine, amiodarone, and thioridazine) were coded and submitted for a blinded test. Of these drugs, eight are reported to induce QT prolongation in the clinic (adriamycin, clomipramine, quinidine, amiodarone, and thioridazine), while three do not lengthen and three shorten the QT. To test for reproducibility, four drugs were given in duplicate (haloperidol, aspirin, erythromycin, and terfenadine). The drug effects on monophasic APD, conduction, instability (index of variability of APD), triangulation (index of duration of fast repolarization), and reverse use dependence were measured at five drug concentrations (0.05, 0.15, 0.5, 1.5, and 5 mg/l). All 14 blinded drugs, in the concentrations used, were correctly identified as to their effects on APD and conduction. The drugs eliciting drug-induced proarrhythmia in patients were also identified as promoting instability, triangulation, and reverse use dependence in the rabbit heart. Importantly, none of the safe agents was labeled as proarrhythmic, and the results were very consistent between duplications. In conclusion, SCREENIT correctly identifies prolongation of APD, accurately separates safe agents form proarrhythmic drugs, and has highly reproducible results. Thus, the isolated perfused rabbit heart can be a valuable tool in a preclinical proarrhythmia test battery in drug development.

[1]  B. Mikulski,et al.  Drug Safety : Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women , 2001 .

[2]  D. Zipes,et al.  Electrophysiological Mechanisms in a Canine Model of Erythromycin‐Associated Long QT Syndrome , 1993, Circulation.

[3]  D. Flockhart.  Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? , 1996, Journal of clinical psychopharmacology.

[4]  J. Rapoport,et al.  Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[5]  J. Kupersmith,et al.  Regional effects of propranolol on intraventricular conduction in coronary artery disease , 1979, Clinical pharmacology and therapeutics.

[6]  J. Mason,et al.  Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. , 1984, Circulation research.

[7]  S Nattel,et al.  The Molecular and Ionic Specificity of Antiarrhythmic Drug Actions , 1999, Journal of cardiovascular electrophysiology.

[8]  T. Narahashi,et al.  Block of sodium channels by psychotropic drugs in single guinea‐pig cardiac myocytes , 1989, British journal of pharmacology.

[9]  R. Rangno.  Terfenadine therapy: can we justify the risks? , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  R. Campbell,et al.  Antiarrhythmic drugs , 1995, Springer Berlin Heidelberg.

[11]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[12]  A. Camm,et al.  Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? , 1998, The American journal of cardiology.

[13]  S. H. Thomas,et al.  Drugs, QT interval abnormalities and ventricular arrhythmias. , 1994, Adverse drug reactions and toxicological reviews.

[14]  John Cotton,et al.  Introductory statistics. 3rd ed. , 1978 .

[15]  T. Campbell.  Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. , 1983, Cardiovascular research.

[16]  M. Veldkamp.  Is the slowly activating component of the delayed rectifier current, IKs' absent from undiseased human ventricular myocardium? , 1998, Cardiovascular research.

[17]  S. Hohnloser,et al.  Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.

[18]  D. Roden,et al.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.

[19]  Cavero,et al.  QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. , 1999, Pharmaceutical science & technology today.

[20]  E. Michelson,et al.  Polymorphous ventricular tachycardia associated with normal and long Q-T intervals. , 1982, The American journal of cardiology.

[21]  P. Gasparini,et al.  [Severe ventricular arrhythmia secondary to indapamide-induced hypopotassemia]. , 1990, La Clinica terapeutica.

[22]  J. Nerbonne.  Molecular basis of functional voltage‐gated K+ channel diversity in the mammalian myocardium , 2000, The Journal of physiology.

[23]  Hua-rong Lu,et al.  Female Gender is a Risk Factor for Drug‐Induced Long QT and Cardiac Arrhythmias in an In Vivo Rabbit Model , 2001, Journal of cardiovascular electrophysiology.

[24]  A Garfinkel,et al.  Cardiac electrical restitution properties and stability of reentrant spiral waves: a simulation study. , 1999, The American journal of physiology.

[25]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[26]  L. Carlsson,et al.  Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. , 1993, The Journal of pharmacology and experimental therapeutics.

[27]  R. Woosley,et al.  Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. , 1998, Journal of women's health.

[28]  D. K. Quek,et al.  Torsade de pointes and sudden death associated with diabetic autonomic diarrhoea--a case report. , 1993, Singapore medical journal.

[29]  L. Carlsson,et al.  Female Gender Does Not Influence the Magnitude of Ibutilide-Induced Repolarization Delay and Incidence of Torsades de Pointes in an In Vivo Rabbit Model of the Acquired Long QT Syndrome , 2001, Journal of cardiovascular pharmacology and therapeutics.

[30]  M. Ferrari,et al.  Cardiac effects of quinidine on guinea‐pig isolated perfused hearts after in vivo quinidine pretreatment , 1997, British journal of pharmacology.

[31]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[32]  P. Podrid.  Proarrhythmia, a serious complication of antiarrhythmic drugs , 1999, Current cardiology reports.

[33]  L. Carlsson,et al.  QTU‐Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit: Etiology and Interventions , 1990, Journal of cardiovascular pharmacology.

[34]  L. Hondeghem.  Computer Aided Development of Antiarrhythmic Agents with Class IIIa Properties , 1994, Journal of cardiovascular electrophysiology.

[35]  C Antzelevitch,et al.  Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. , 1996, Journal of the American College of Cardiology.

[36]  G. Gintant,et al.  The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.

[37]  L. Hondeghem,et al.  Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. , 2001, Cardiovascular research.

[38]  H. Masumiya,et al.  Inhibitory effects of terfenadine on the rising phase of action potentials and sinus rates in isolated guinea-pig myocardium. , 1996, General pharmacology.

[39]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[40]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[41]  B. Katzung,et al.  Test of a Model of Antiarrhythmic Drug Action Effects of Quinidine and Lidocaine on Myocardial Conduction , 1980, Circulation.

[42]  A. Garfinkel,et al.  Chaos and the transition to ventricular fibrillation: a new approach to antiarrhythmic drug evaluation. , 1999, Circulation.